A significant study conducted by the department of pulmonary medicine at Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS) in Lucknow reveals that nearly 40% of patients with pulmonary sarcoidosis experience a relapse after treatment is reduced or discontinued. The research, published in the journal Respiratory Medicine, analyzed data from 51 studies involving 6,093 patients across various regions, including India, Europe, and North America. It found that the majority of relapses occur within 18 months of stopping therapy, with the highest risk noted between 6 and 12 months. Patients with advanced lung disease are particularly vulnerable to relapses, underscoring the necessity for continuous follow-up to mitigate complications. The study also highlights the increasing recognition of sarcoidosis in India, where it affects 6-12 individuals per lakh population. Prof Zia Hashim, who led the study, emphasized the importance of ongoing monitoring for patients, especially those previously treated for tuberculosis, as many sarcoidosis cases are diagnosed at advanced stages due to the high burden of TB in the country.